PAION AG

Official site of PAION AG. PAION AG is a specialty pharmaceutical company developing and aiming to commercialize innovative drugs for sedation and anesthesia.

[PAION AG @PaionAG]

We had the pleasure to host a symposium at the 42nd ISICEM congress which was a great success for our company. The great feedback from the participants motivates us to push forward our activities in R&D and commercialization of our products.

[PAION AG @PaionAG]

Great news! We are excited that the European Commission has approved remimazolam, and thank all healthcare professionals, patients and partners who have been involved in the development of remimazolam.
https://t.co/7B1P7xZ0xS

[PAION AG @PaionAG]

PAION is proud to participate at the ISICEM 2023, International Symposium on Intensive Care and Emergency Medicine, in Brussels. We are looking forward to seeing you there.
https://t.co/mAGgtMOamM

[PAION AG @PaionAG]

Great achievement: PAION receives positive CHMP opinion recommending approval of remimazolam for the induction and maintenance of general anesthesia in adults.
https://t.co/BbV6KzdF1P

[PAION AG @PaionAG]

Extraordinary General Meeting approves capital reductions and creates scope for further corporate financing.
"We are pleased that our shareholders have voted with a large majority in favour of the implementation of a capital reduction."
https://t.co/CmboqOqn1J

[PAION AG @PaionAG]

PAION announces submission of New Drug Application for remimazolam by its licensee Cristália in Brasil. Congratulations to our partner Cristália!
https://t.co/o9inhivTVr

[PAION AG @PaionAG]

@PaionAG enters partnership with Viatris and expands sales activities in Europe

https://t.co/xxgf1E8Y6X

[PAION AG @PaionAG]

@PaionAG quarterly statement for the first nine months of 2022

https://t.co/kLG3AwPIhb

[PAION AG @PaionAG]

@PaionAG half-year report 2022
https://t.co/AuZuq2fLda

[PAION AG @PaionAG]

@PaionAG reports solid progress with commercial activities in Europe

https://t.co/AVrJkfgCmB

[PAION AG @PaionAG]

Annual General Meeting approves all agenda items and elects Michael Schlenk and Gregor Siebert to the Supervisory Board
https://t.co/eirFvFr0E3

[PAION AG @PaionAG]

We welcome Cristalia as our new remimazolam partner for Latin America!

PAION grants exclusive license to Cristália for development and commercialization of remimazolam in Latin America
https://t.co/87yMbEus8e

[PAION AG @PaionAG]

PAION assigns Chinese remimazolam patents and sells related future royalties for EUR 20.5 million to Humanwell Healthcare Group
https://t.co/w1f5kKdS4h

[PAION AG @PaionAG]

PAION submits extension application of marketing authorization for Remimazolam in the indication general anesthesia to the European Medicines Agency
https://t.co/Eec6HgxGQ1

[PAION AG @PaionAG]

@PaionAG quarterly statement for the first nine months of 2021
https://t.co/oHMDamQOxs

[PAION AG @PaionAG]

Happy #WorldAnesthesiaDay2021 to all #TeamAnaesthesia! At PAION, our mission is to support and partner with proceduralists and anaesthetists to evolve the field of procedural sedation and anaesthesia together. #WAD2021

[PAION AG @PaionAG]

PAION Insights Newsletter

Please, read on!
https://t.co/vaM3hdNGlQ

[PAION AG @PaionAG]

@PaionAG announces initiation of pivotal study of remimazolam (Byfavo®) in pediatric procedural sedation
https://t.co/HooiDkJniu

[PAION AG @PaionAG]

Today is World Sepsis Day! Sepsis is still the number one cause of death in hospitals.
Join the fight against #sepsis! #WorldSepsisDay2021 #September13

[PAION AG @PaionAG]

@PaionAG launches XERAVA® (eravacycline) for the treatment of complicated intra-abdominal infections in adults in the Netherlands

https://t.co/oVG0n3dIfq